 |
|
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Shan Shan, Jidong Jia
Clin Mol Hepatol. 2023;29(2):339-341. Published online 2023 Mar 16 DOI: https://doi.org/10.3350/cmh.2023.0077
|
|
Citations to this article as recorded by
 A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen
Yawen Xie, Yanxia Huang, Shuyue Liu
Nursing in Critical Care.2025;[Epub] CrossRef Exploring the association between air pollution and the incidence of liver cancers
Xin Wu, Xin Zhang, Xiaopeng Yu, Hongyuan Liang, Shaoshan Tang, Yao Wang
Ecotoxicology and Environmental Safety.2025; 290: 117437. CrossRef Dual-Functional Micelles for Codelivery of Sorafenib and Dehydrodiisoeugenol in Treatment of Hepatocellular Carcinoma
Su-Yu Yang, Shu-Tong Li, Tian-Hua Li, De-Jin Ma, Jun-Jie Yu, Yang Liu, Yang Yu, Xue-Tao Li, Juan Zang, Zi-Min Yuan, Liang Kong
ACS Applied Nano Materials.2025; 8(11): 5355. CrossRef Preparation and Evaluation of Hepatoma-Targeting Glycyrrhetinic Acid Composite Micelles Loaded with Curcumin
Xueli Guo, Zhongyan Liu, Lina Wu, Pan Guo
Pharmaceuticals.2025; 18(4): 448. CrossRef How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990–2019
Nelson Alvis-Guzman, Nelson J. Alvis-Zakzuk, Fernando De la Hoz Restrepo
Microorganisms.2024; 12(2): 388. CrossRef β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression
Ruoyu Wang, Dan Tang, Longyun Ou, Jiacheng Jiang, Yu-nan Wu, Xuefei Tian
Human Cell.2024; 37(4): 1156. CrossRef Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma
Deming Li, Ting Zhang, Ye Guo, Cong Bi, Ming Liu, Gang Wang
Cell Death & Disease.2024;[Epub] CrossRef Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody
Shichuan Tang, Tingfeng Huang, Cong Luo, Jun Fu, Kailing Zhang, Qingjing Chen, Jie Kong, Jianxi Zhang, Zhenghong Sun, Yongkang Diao, Kongying Lin, Yongyi Zeng
iLIVER.2024; 3(3): 100109. CrossRef Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
Hongfu Cai, Jingwen Lin, Huide Zhu, Zhiwei Zheng
BMJ Open.2024; 14(12): e079603. CrossRef
|